Another study showed that deficiency of the Rela/Stat3-CYP enzyme pathway in mouse liver led to a decrease in primary BAs and ameliorated colitis, suggesting that inhibitors of this pathway could offer a novel mechanism to control inflammation in IBD through the gut–liver axis [98]. This evidence concerns the gene STAT3 and colitis.